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Abstract 
 
It is estimated that 20-25% of adults in the world have metabolic syndrome (MetS), and 
in Chinese population this has become an important public health problem. MetS is 
characterized as cluster of metabolic disorders that lead to cardiovascular diseases or 
type 2 diabetes mellitus, and is diagnosed through the identification of three out of five 
possible risk factors: central obesity, increased blood pressure, increased fasting blood 
glucose, increased serum triglycerides and decreased HDL-cholesterol. Although the 
diagnosis of MetS is possible, its underlying mechanisms are yet to unveil, and new 
approaches are needed to explore the metabolic disorders and provide better diagnosis 
methods. Metabolomics has proven to be a powerful tool in biomarker identification 
providing metabolic information in several clinical fields. In this study, a metabolomics 
approach is used for free fatty acid (FFA) profiling by gas chromatography-mass 
spectrometry (GC-MS) of MetS serum samples of Chinese patients, and a combined 
chemometrics strategy using principal component analysis (PCA), random forests (RF) 
and canonical correlation analysis (CCA) is applied for classification and biomarker 
identification. After optimizing the derivatization and program temperatures for GC-MS 
analysis, an FFA analysis based on experimental design and internal quality control 
procedures is performed, with demonstrated reliability though the continuous evaluation 
of quality control (QC) samples. The classification results from PCA and RF confirm 
the good performance of the QC samples, and the later method is able to classify MetS 
samples and healthy control (HC) samples efficiently, with an accuracy of 0.8632. From 
CCA the results show a canonical correlation coefficient of 0.9015, indicating a high 
correlation between the clinical parameters and FFA. The most relevant clinical 
parameters for this correlation are shown to be HDL-C, TG and FBG, while the FFA 
that have the most influence in the correlation are C16:1n-9c, C20:1n-9c, and C22:4n-
6c, which are identified as potential biomarkers. Results suggest that targeted metabolic 
profiling of FFA by GC-MS coupled with chemometrics tools such as RF and CCA are 
able to provide important information for biomarker discovery and disease mechanism 
investigation on MetS. 
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1. Introduction 
1.1 Objectives 
This study aimed at the serum fatty acid profiling of Chinese Metabolic Syndrome 
(MetS) patients by gas chromatography (GC) coupled to mass spectrometry (MS), and 
the establishment of a predictive model for classification of MetS samples in the 
Chinese population. In order to fulfil such aims, secondary objectives were set: 
1.1.1 The achievement of repeatability conditions through the improvement of the 
derivatization steps and chromatographic temperature programs. 
1.1.2 The development of an internal quality control procedure including 
experimental design, the use of internal standards and the use quality control 
samples. 
1.1.3 The determination of fatty acid profiles and achievement of a classification 
model using principal component analysis (PCA) and random forest (RF) 
machine learning algorithms after pre-processing. 
1.1.4 To relate the disease classification patterns with its diagnosis factors by 
means of canonical correlation analysis (CCA). 
1.1.5 To identify the potential biomarkers for the disease based on the 
classification results. 
1.2 Literature Review 
Health problems often have a high impact on the development of a country, affecting 
its social and economic status due to the increasing of poverty in the community and the 
decrease of active working citizens. Between 2000 and 2011 the world mortality 
increased almost 4%, with Non-communicable diseases (NCD) being the leading group, 
representing approximately 63% of the global death number in 2008
1,2
. NCD involve 
heart diseases, stroke, cancer, chronic respiratory diseases and diabetes, and have 
several identified modifiable risk factors. A particular cluster of some of these risk 
factors that lead to Cardiovascular Diseases (CVD) and type 2 Diabetes Mellitus 
(T2DM) is defined as Metabolic Syndrome
3–5
. In China, there have been studies 
reporting a high incidence of MetS with a potential of having a great impact on Chinese 
public health
6
.  
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1.2.1 Metabolic Syndrome 
MetS was firstly described in the 1920s by Kylin
7
 as a cluster of hypertension, 
hyperglycaemia and gout. However, it took until 2005 for a consensus statement from 
the International Diabetes Federation (IDF) to be published. Meanwhile, the Chinese 
Diabetes Society (CDS) stated in 2004 that a MetS patient is an individual who satisfies 
any three or four risk factors among central obesity (BMI ≥ 25.0 kg m-2), raised blood 
pressure (SBP/DBP ≥ 140/90 mmHg or hypertension patients), raised plasma glucose 
(fasting plasma glucose ≥ 6.1 mmol/L or diabetes) together with raised plasma 
triglycerides (TG ≥ 1.7 mmol/L) and/or reduced HDL-cholesterol (HDL-C < 0.9 
mmol/L). The several international criteria (WHO, NCEP:ATPIII, CDS) in force 
present slight changes, and are also affected by ageing, physical inactivity, 
proinflammatory state, life style bias and country/ethnic group. It is estimated that about 
20-25 percent in world’s adults have MetS and they are twice as likely to die from and 
three times as likely to have a heart attack or stroke compared with people without this 
syndrome. In addition, people with MetS have a fivefold greater risk of developing 
T2DM. They would join to the 230 million people in the world who already have 
diabetes, one of the most common chronic diseases worldwide and the fourth or fifth 
primary cause of death in the developed world. Therefore IDF acknowledges the 
urgency for a better understanding of MetS and for long-term research for “measuring 
more precisely a wide range of variables”3 and “establishing the most predictive 
markers”3. Despite the MetS criteria being well known, its variability in the diagnosis 
(any three of the risk factors can be taken into account to the MetS condition) leads to 
problems in consistency and questions about whether individuals that have one or two 
of the risk factors may be considered as MetS patients or healthy, and if healthy, how 
close they are to be MetS patients
3,8–13
.  
As previously described, MetS involves a particular number of risk factors that are 
well known to be also risk factors for obesity, T2DM and CVD individually, having 
their individual proposed biochemical pathways. As shown in figure 1, some proposals 
for the biochemical behaviours that occur in the presence of MetS have been done
5
.  
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  Figure 1: MetS proposed biochemical pathways
5
.  
When a significant amount of adipose tissue mass is accumulated in the human body 
there is a release of free fatty acids (FFA) which will act in the liver as promoters of 
glucose production, and being incorporated in TG and very low density lipoproteins 
(VLDL). In addition, HDL-C is decreased concomitantly with the increase of low 
density lipoproteins (LDL). The action of FFA is extended to the inhibition of insulin-
mediated glucose uptake in the muscle, which consequently will stimulate its 
accumulation in the blood stream. As a parallel result, glycogen synthesis is inhibited 
due to the low concentration of glucose in the muscle and intramuscular droplets of TG 
are formed due to the excess of FFA. Nevertheless, FFA seem to stimulate the insulin 
secretion in the pancreas, leading to an hyperinsulinemia status which ultimately results 
in the increased activity of the sympathetic nervous system (SNS), which together with 
the FFA will lead to hypertension. Such mechanisms summarize the phenomena of 
insulin resistance, increased BMI/waist circumference (WC) due to intra-abdominal or 
visceral adipose tissue, dyslipidaemia (focusing on VLDL, HDL-C, LDL and FFA), 
glucose intolerance due to insulin dysregulation, and hypertension mediated by FFA
14
 
and SNS. 
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Much information on the specific pathways affected by the metabolomic changes in 
the organism have been gathered in recent years
5,9,11,15–17
, however specific information 
on the FFA profile present in the serum samples of MetS patients is yet to unveil. 
1.2.2 Fatty Acids and Serum Sampling 
Commonly, a fatty acid (FA) is biochemically defined as a long chain of carbon 
atoms linked to a carboxylic acid functional group, and are the key constituents of 
lipids. The degree of unsaturation (number of double bonds) or saturation, and their 
number of carbons, are the main characteristics responsible for their nomenclature and 
simultaneously for their biochemical properties. As the example shown on figure 2, a 19 
carbon length FA with an unsaturation on the 10
th
 carbon is designated by Z-10 
nonadecenoic acid or cis-10-nonadecenoic acid (using a systematic nomenclature 
accordingly to the International Union of Pure and Applied Chemistry (IUPAC) 
recommendations), but also other nomenclature ways may refer to the same compound 
as cis-Δ10 nonadecenoic acid (where the superscript number indicates the position of the 
double bond counting from the carboxylic acid group, and the prefix shows the structure 
conformation), as ω-9 nonadecenoic acid (where the number after the omega is the 
location of the double bond counting from the methyl group located next to the carbonyl 
carbon), or simply as C19:1(cis-10), describing in a very straightforward way the 
number of carbons and unsaturations as well as the position and conformation of the 
double bond. Nevertheless, some “trivial” or historical names may be considered in 
scientific writing depending upon convenience
18,19
.  
 
Figure 2: 10-nonadecenoic acid structure
20
 
In nature, FAs can be found in several types of sources which contain either fats or 
oils
19
. In the human body these molecules are involved in many processes and can be 
found incorporated in phospholipids (generally one or more FA linked to a glycerol, 
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which has a phosphate-alcohol group attached to it) and consequently forming 
biological membranes. Their amphipathic properties allow a selective permeability 
(hydrophilic polar glycerol side versus the hydrophobic apolar FA part) in membranes, 
a diverse organization of the several phospholipids in the membrane depending on their 
unsaturation degrees (allowing a dynamic fluidity) and relative percentage of each, and 
also a tolerance to the integration of molecules with biological functions (glycolipids, 
channel proteins, cholesterol and others). Indeed, FAs play an important role in the 
human body, being also a source of energy while stored as TG (three FA chains bonded 
to a glycerol molecule), often in fat deposits or originated from dietary fats. These 
molecules have as main characteristic being nonpolar, and their main storage location is 
the adipose tissue, being mobilized to other tissues when energy is needed, in the form 
of FFA. In the biological pathways, this process is carried on by specific lipases that do 
the cleavage by hydrolysis. In the blood plasma, these FFA are then transported by the 
circulating albumin being finally assimilated in the target cells by specific membrane 
proteins, and oxidized by the respective metabolic pathways which will origin energy in 
the form of ATP (Adenosine Triphosphate) via the citric acid cycle (CAC), as shown in 
figure 3
18,19
.  
 
Figure 3: Triglyceride metabolic pathways and their location
18
 
Some common analytical techniques such as GC-MS require the FAs to be 
derivatized after the extraction step, making them volatile in order to allow their elution 
through the chromatographic column. These derivatives are often fatty acid methyl 
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esters (FAMEs), which can be easily obtained by common methylation techniques 
involving the addiction of an acid-methanol mixture (e.g. H2SO4, HCl, BF3) as 
described in figure 4. 
 
Figure 4: Five-step basic mechanism of FA methylation 
In a first step there is the attack of the acidic proton (from the H2SO4) by the non-
bonding electrons of the carbonyl group. The carbon of the carbonyl group will then 
have a reduced electron density that will stimulate a nucleophilic attack from the non-
bonding electrons of the oxygen in the methanol (MeOH). After step 2, a four-bond 
carbon is formed; the MeOH oxygen will attract the electrons that establish its bond 
with hydrogen, making it vulnerable to the attack of any of the other two adjacent 
hydroxyl groups. As a result a leaving group is formed (H2O) and an unstable 
carbocation is generated, leading ultimately to the formation of a double bond with the 
hydroxyl group and simultaneously to the release of the labile hydrogen of the same 
functional group. The final outcome will then be the establishment of a FAME 
compound
21
.  
Based on this procedure several approaches were described in literature, leading to 
the use of different kinds of acids and solvents, and specifying the type of FA to be 
methylated, both in plasma
19,22,23
 and serum samples
24
; EFA (esterified fatty acids) or 
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NEFA (non-esterified fatty acids). While EFA exist in the biological context as 
phospholipids, glycolipids and lipid sterols, NEFA are generally found linked to 
albumin molecules. Each of these FA types have a specific derivatization before 
analysis because NEFA need to be separated from the albumin, while EFA need to be 
cleaved from their associated polar moieties
22,23
. The latter are not bioactive since they 
require more complex reactions to be released into the blood stream. In fact, after some 
research on the influence of FA on the classification of metabolic-related disease 
groups, it was noted that EFA show no significant effects on the discrimination of 
T2DM and control groups
25
. Considering this, our study developed a derivatization 
procedure focused only on NEFA, as shown in figure 5. 
 
Figure 5: General methodology for FA extraction 
Prior to FA extraction, one has to carry out the biological sampling which is a critical 
step in the analytical process. In the quality assurance cycle, three phases can be 
identified: pre-analytic, analytic and post-analytic. In the pre-analytic stage there is the 
Mix 
Serum+IS+KO
H 
Incubate at 
room 
temperature 
Extract 
with 
hexane 
Isolate 
serum phase 
and add 
Na2SO4 and 
H2SO4 
Incubate 
at 70ºC 
Extract 
with 
Hexane 
Isolate 
organic 
phase and 
evaporate 
under N2 
flow 
Solubilize 
in hexane 
and analize 
by 
GC-MS 
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sample collection, test evaluations, sample transport (in case the sampling is done in a 
different place from the one where is the storage) and sample storage. The analytic stage 
is where the actual analysis is performed by doing the testing and quality control. 
Lastly, the post-analytic stage is where the results are recorded, processed by doing the 
data analysis and ultimately the final version of the results are reported. In an accredited 
laboratory, the pre-analytical phase is defined by ISO 15189:2012 standard for 
laboratory accreditation as the “processes that start, in chronological order, from the 
clinician’s request and include the examination request, preparation and identification of 
the patient, collection of the primary sample(s), and transportation to and within the 
laboratory, and end when the analytical examination begins” 26. Such a definition helps 
us to understand the need to control and understand the processes that happen during the 
initial phase of the analytical process. It is estimated that approximately 60% of the 
clinical laboratory errors happen in the pre-analytic stage. The main causes of these are: 
specimen collection tube not filled properly; patient ID error, inappropriate specimen 
collection tube; test request error: and empty collection tube
27
. These errors will 
ultimately lead to problems related with contaminations, sample degradation or wrong 
result delivery, which can be minimized by the use of standard operating procedures 
(SOP) and taking corrective actions for continuous improvement. In the specific case of 
FA, avoiding hydrolysis and autoxidation is a concerning factor. When working with 
biological tissues, and particularly with serum samples, the blood collection is followed 
by an incubation period and a centrifugation step, resulting in the isolation of the serum 
phase containing the compounds present in the blood stream. This phase shall be stored 
at temperatures below -70ºC in a nitrogen atmosphere due to the possibility of 
enzymatic activity and consequent degradation of FA
19,28
.  
As described before, several errors may arise from inaccurate experimental handling 
and specimen collection, influencing laboratory measurements (e.g. high-negative-
pressure blood draws, non-fasting patients, insufficient tube filling, bacterial 
contamination, among others). Unlike plasma, serum samples are allowed to pass 
through the coagulation process avoiding the presence of clotting factors, but potentially 
masking the levels of certain biomarkers. These two blood-derived matrixes are 
commonly used interchangeably; however it is known that proteomes and other 
biomarkers present different profiles depending on the chosen matrix
19,28
. Due to the 
lower protein concentration on serum, lower demands on sample pre-treatment are 
required and a lower risk of treatment may influence the results (e.g. incubation 
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affecting analyte peak areas) 
29
. On the other hand, the differences between serum and 
plasma seem not to be of clinical relevance, despite the statistical significance presented 
for compounds other than FA
30
.  
Accordingly to previous knowledge, in order to reduce changes in the serum analytes, 
each sample shall use the same kind of collection tubes relatively to the manufacturer 
and material type (significant difference found in growth factors, insulin, hormones and 
antigens) 
31–33
. As stated before, serum is usually allowed to coagulate and therefore a 
waiting time is required before centrifugation. Obviously this shall be a controlled time 
if one needs to maintain repeatability and reduced sample variability conditions. This 
time is estimated to be between 30 and 60 min and will allow the precipitation of 
cellular components that may affect the downstream analysis, but in some cases more 
time is need due to the presence of anti-coagulant agents in the sample (e.g. previous 
drug treatment applied in the patient) 
34,35
. After the coagulation process, immediate 
freezing storage is needed at the previously mentioned temperature of at least -70ºC in 
order to maximize sample quality
36,37
. Despite some works have shown a reliability 
limit of 1 serum freeze-thaw cycle
38
, there are evidences that FA are able to stand up to 
5 cycles with low relative standard deviation (RSD) values, particularly for EFA rather 
than NEFA
23
.  
1.2.3 Gas Chromatography and Mass Spectrometry  
The MetS diagnosis proposals by the several national and international organizations 
are based on simple tools preferred by clinicians to evaluate the biochemical status of 
the patient, facilitating the clinical practice
5
. In the same way, GC-MS is among the 
most widely used analytical techniques for high-throughput analysis, allowing the 
analysis of large amount of samples in a relatively short time by researchers around the 
world. 
Chromatography is defined by IUPAC as “a physical method of separation in which 
the components to be separated are distributed between two phases, one of which is 
stationary (stationary phase) while the other (the mobile phase) moves in a definite 
direction”39. This is a very clear definition that describes a method initially developed 
by Mikhail Tswett in 1903 for the separations of pigments in green leaves
40
, but 
established later by Martin and Synge in 1941 during the development of the “Theory of 
Chromatography”41, having the later been awarded a Nobel Prize in Chemistry (1952) 
“for their invention of partition chromatography” 42. As shown in figure 6, the 
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chromatographic process is based on a successive series of equilibria established 
between the two phases, the mobile phase (also called eluent) which contains the 
analyte, and the stationary phase (in the case of a packed column, it is referred as the 
packing material, otherwise it is referred as the coating of the column). These equilibria 
are based on the composition of each of the phases, and their affinity to each other. For 
instance, a certain analyte which possesses polar characteristics will be more retained in 
a more polar stationary phase, eluting later in the chromatogram (right side of figure 6 
(b)) than another analyte, which possesses apolar characteristics and shows greater 
affinity for the mobile phase. Such interactions can be easily manipulated by using 
different stationary and mobile phases, promoting faster and more efficient separations 
between the analytes of interest. 
 
Figure 6: (a) General chromatographic process (b) Chromatogram example
43
 
Chromatography can be divided into two main types: planar and column 
chromatography. In the case of planar chromatography, there is a planar support (a 
plate) which is coated with the stationary phase, and where the analytes are placed. 
Afterwards, these supports are put in contact with the mobile phase which is a liquid 
phase that adsorbs to one of the edges of the plate and moves by either capillarity of 
gravity, crossing all the plate and resulting on the migration of each of the analytes 
through the stationary phase. On the other hand, column chromatography is performed 
in a column/tube (as illustrated in figure 6) that can be packed with the stationary phase 
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or simply coated. In the case of a packed column, the mobile phase moves by gravity or 
pressure, and the analyte is introduced at the top of the column, migrating though the 
column accordingly with the type of chromatography (normal phase, ion exchange, 
reversed-phase, affinity, size exclusion…). Thus, the column packing will define the 
relationship between the analyte and the stationary phase, and consequently influence 
the interaction of the analyte with the mobile phase. Independently of the column 
packing, the chromatographic process will always produce a chromatogram that results 
on the signal detection along the time. A more retained analyte will have a larger 
fraction of time spent in the stationary phase, then a less retained analyte, leading to the 
generation of different bands in the chromatogram that can afterwards be analysed 
quantitatively and qualitatively. In general, the analytes are diluted in the 
chromatographic process due to diffusion, which means that more sensitive detectors 
are needed for this kind of analysis. Many factors may be adjusted in order to improve 
the separation of the analytes. One of these is column performance, which is increased 
by the increase in the column length. This will provide a better peak separation, 
however peak broadening also happens, thus it becomes difficult to adjust this 
parameter. Ideally a good separation needs to increase band separation and decrease 
band spreading, and these factors depend directly on the rate of distribution of each 
analyte between the mobile and stationary phase. This means that, by selection of an 
appropriate stationary and mobile phase, this separation can be manipulated. In this 
way, we can access an approximation of the column efficiency by analysing the peak 
width in a chromatogram. 
When talking about column efficiency and band broadening it is mandatory to refer 
to the Van Deemter equation
44
, which describes the general mechanisms of band 
broadening in linear nonideal chromatography. This equation considers factors such as 
Eddy diffusion, longitudinal diffusion and mass transfer, and relates these with the plate 
theory of Martin and Synge
41
. In this theory, the column is theoretically divided in a 
number of layers called theoretical plates, as shown in figure 7, in which the mobile 
phase is able to reach a series of equilibriums in each theoretical plate. 
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Figure 7: illustration of theoretical plate division of chromatographic columns 
In this model, when the number of theoretical plates (N) increases, the efficiency of the 
separation increases as well. In the same way, the separation efficiency increases when 
the height (H) of each theoretical plate decreases. These variables can be related with 
the column length (L) using equation 1: 
(1)          𝑁 = 𝐿 𝐻⁄  
Knowing this, it is possible to understand the assumptions of the Van Deemter equation 
(equation 2): 
(2)          𝐻 = 𝐴 + 𝐵 𝑢⁄ + 𝐶 ∙ 𝑢 
in which A is the Eddy diffusion coefficient, B is the longitudinal diffusion coefficient, 
C is the mass transfer coefficient and u is the linear velocity of the mobile phase. The 
coefficient A represents the channelling (presence of preferential paths), and this can be 
minimized by using uniform stationary phases and low particle diameter. The B 
coefficient shows the spreading effect of the analytes along the analysis, which can be 
minimized by increasing the flow rate (a critical factor in gas chromatography due to the 
high gas diffusion). The C coefficient considers the difference in the movement of 
particles in the mobile phase and in the stationary phase, due to the equilibrium 
phenomenon, and is more significant in liquid chromatography. The later can be 
reduced by increasing the column temperature. 
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Figure 8: variation of theoretical plate height (H) with linear velocity of 
mobile phase (u) 
As shown in figure 8, it is possible to estimate an optimal flow rate of the mobile phase 
in order to minimize H, by adjusting the 3 mentioned coefficients. 
Apart from the column contribution for band broadening, there is also an outside of 
column contribution which is related to other parts of the chromatographic system. 
Components like the injector, the connecting lines to the column, connecting lines to the 
detector, and also the geometry and characteristics of the detector, are significant points 
to consider. 
Applications of chromatography are many, as this separation method can be used for 
both qualitative and quantitative analysis. The retention times shown in the 
chromatograms and the manipulation of mobile and stationary phases together with the 
different elution temperatures, provide a characteristic data set for a single sample type, 
allowing identification. On the other hand, the measurement of peak areas or heights, 
and their comparison with standard references, makes possible the quantitative analysis, 
in which it is extremely important to control peak broadening factors. The use of peak 
areas is in fact less influenced by these effects and is the preferred method of 
quantitation. 
Gas chromatography is a fast technique that uses a vaporized sample, which is 
partitioned between the mobile phase (an inert gas) and the stationary phase (a solid or 
liquid layer coating the column). It is not necessary large amounts of sample, and after 
the injection of the sample in the column head, the mobile phase carries the analytes 
without interacting with it, thus allowing a separation based on the interaction between 
the analytes and the stationary phase. The two types of GC are Gas-solid 
  INTRODUCTION 
Page | 14  
 
chromatography (GSC) and Gas-liquid chromatography (GLC), depending on the phase 
of the stationary component. In the first type, there is the risk of semi-permanent 
adsorption of the analytes to the stationary phase, which will result in peak tailing, or 
column saturation, which is an important limitation. In GLC, commonly named GC, 
there is a thin liquid coating layer on the capillary tubing, avoiding the limitations of the 
previous chromatographic type, making this a widely used method. When comparing 
the Van Deemter curves for LC and GC, it is possible to see that optimal flows for GC 
are higher than for LC, making GC a faster method. In addition, it is generally found 
that H are typically higher for GC (also due to the possibility of having much longer 
columns) leading to a superior efficiency. The fact that GC uses high temperatures and 
volatile samples makes it easier to couple it with MS detectors (as shown in figure 9), 
since MS also requires volatile samples. 
 
Figure 9: diagram of GC-MS-computer coupled system
45
 
Among other types of detectors, MS is a powerful technique able to identify a 
compound based on its fragmentation pattern, by evaluating the mass-to-charge ratio 
(m/z) of the charged particles generated in the fragmentation process. Consequently it is 
a destructive method, not allowing the recovery of the sample after analysis. The 
particles can be either molecular ions, isotope ions or even fragment ions, but the 
resultant detection is based on mass, charge and speed. 
In general this coupled system works by using an autosampler to load the sample into 
the GC column inlet. The sample then passes through the column with the help of the 
carrier gas and reaches the transfer line between the chromatograph and the mass 
spectrometer. A rubber or silicone septum is located at the inlet, ensuring an isolation of 
this section during the sample injection (as shown in figure 10). 
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Figure 10: Sample port diagram 
The sample port should be 50ºC higher than the boiling point of the least volatile 
component of the sample. The process of injection may happen in different modes: split, 
splitless, on column or programmed temperature vaporising. In this work it was used a 
split injection mode, where the sample is introduced into a heated injection chamber 
(where the evaporation occurs) and mixed with the carrier gas. This mix is then vented 
into the split exit and only a part of this mix is allowed into the column. By adjusting 
the split ratio, it is possible to control the amount of sample that enters the column (ex: 
1:5 split ratio means that in each 5 parts injected, only 1 part enters the column). This 
mode is not suitable for trace analysis, since a low sample volume is analysed, however 
it helps to avoid column saturation and to obtain narrow bands. Moreover, in order to 
avoid the reaction of the analyte with the metal surface of the injector, it is necessary to 
use liners, which most of the times have a glass wool filling that blocks the passage of 
pieces of the septum or non-volatile particles of the sample. 
The column is placed in an oven that will control the temperature during the process, 
while the mass spectrometer is placed in a different section under vacuum conditions. 
Nowadays, most applications use capillary columns (open tubular) due to their higher 
efficiency. Their length makes it easier to place them in the oven as coils. In most 
analyses, a column temperature program is necessary, due to the different boiling points 
of the components of the sample and the need to avoid exceeding the temperature limit 
of the column. At low temperatures better resolutions are often found, however the 
analysis time is longer. 
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After passing through the column, the sample is directly transferred to the mass 
spectrometer (in the case of capillary columns), where it is received in the ion source. 
At this point, the sample is in a volatile state and undertakes electron ionization by the 
accelerated electron beam generated by the instrument, as following: 
𝑀 + 𝑒− → 𝑀+ ∙ +2𝑒− 
where M is the original molecule. 
In order to obtain a good chromatographic profile, the full scan range should be set to 
a higher m/z than the one of the molecular cluster ions (allowing inclusion of all the 
fragments). After this step, only the charged species will proceed to the mass analyser, 
passing through the focusing lens. The most common analysers are Quadrupoles, Ion 
Traps and Time-of-Flight (TOF). Quadrupoles consist of 4 electrodes placed in parallel, 
building scanning lines that work as selective m/z filters, operating at relatively low 
vacuum and being easier to couple with other analysers (tandem analysis). In Ion Traps, 
the ions reach a ring electrode in a chamber in which the ion motion is damped by a 
buffer gas (generally helium). Presenting a higher cost, TOF has a wide m/z and high 
scanning speed, using also a high vacuum. This last technique uses a non-linear ion 
route, making the ions travel from the ion source through a magnetic field called 
Reflectron, spreading the ions according to their energies, allowing a better selection in 
the detector. In this work, a single quadrupole MS was used for analysis. 
As a result, the GC-MS system is able to provide a 3-dimensional data set of 
retention times, m/z and signal, as shown in figure 11. 
 
Figure 11: Gas Chromatography-Mass Spectroscopy data set illustration
46
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Such data sets can be obtained in two ways: full scan or SIM (Selected Ion Monitoring). 
In short, a full scan mode will register all the fragments obtained during the analysis 
time, making this detection type useful for the determination of unknown compounds or 
for identifying fingerprints prior to SIM mode. On the other hand, SIM mode allows the 
detection of the intensity of few previously selected ions along the analysis time, 
providing a lower detection limit (targeted analysis) and less matrix interference, thus 
allowing quantitative analysis to be carried out. Nevertheless, it is important to always 
use reference standards to ensure identification of the mass fragmentation patterns. 
Generally, an internal standard is mixed with the sample, in order to increase the 
precision of analysis and to overcome the high instability between successive injections 
(e.g.: imprecision in sample volume due to small volumes and evaporation from 
injection needle). The internal standard used should be pure and not react with other 
components in the sample, have a similar retention time (same structural family), well 
resolved elution peak from other components, and obviously not be present in the 
original sample. 
Before data analysis, it is important that the GC-MS parameters are optimized so that 
good resolution and separation is achieved. However, there are external factors that may 
also influence the experimental results. Among these factors are the high temperatures 
in several components of the system, carrier gas flow, stationary phase age and column 
dimensions. 
1.2.4 Metabonomics and Metabolomics 
In systems biology, one of the tools to control and explain biological complexity is 
metabolomics, providing information about molecular processes in cells, tissues, organs 
or organisms, focusing on metabolites and their profiles (leading to organism 
phenotypes). Fiehn states that metabolomics is “a comprehensive and quantitative 
analysis of all metabolites in a system”47, while Nicholson uses another commonly used 
interchangeable term, metabonomics, described as the profiling of the whole metabolite 
composition in a living system, accounting for their changes due to environmental 
conditions and genetic background
48
. Independently of the term used, metabolomics 
studies offer the opportunity to quickly identify changes in the metabolome (range of 
metabolites present in a certain organism) due to the close relationship between the 
metabolic profile and the phenotype (observable properties of a certain organism). 
Metabolites are low-molecular-weight compounds that are involved in several 
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biochemical pathways, often found as reagents or products in metabolic processes, or as 
part of structures such as proteins, nucleic acids or organelles (membranes, cell 
walls…), having sometimes importance in signalling mechanisms. Thus, such 
molecules are fundamental in pathological studies and biomarker discovery, and their 
analysis may lead to the better understanding of diseases and consequently, to better and 
faster diagnosis methods or ultimately to drug development. When compared with other 
“-omics” studies, metabolomics has as main advantage the possibility of observing the 
direct consequence of system perturbations though the metabolome composition
49
.  
Metabolomics profiling is one of the strategies that can be used as a first approach to 
access the metabolome of an organism, and is carried out with the use of powerful 
detectors such as MS. Coupled with GC, this technique is one of the most widely used 
due to their adaptability to high-throughput analysis (typically less than 30 minutes per 
sample), low instrument cost (comparing with NMR) low sample cost and volume, 
good sensitivity and reproducibility, high reliability, ease of use, and the its transferable 
library (independent of the manufacturer). However, some limitations may be found 
since there is a need of sample pre-treatment (volatile samples are needed), it is a 
destructive method (sample cannot be recovered), and some maintenance is needed 
between runs. Ideally, in order to acquire the highest range of metabolites in the matrix, 
it would be necessary to involve other analytical methods (such as NMR or UPLC-MS, 
as example), but in the present study there is a special concern in the analysis of FFA in 
serum samples, which reduces significantly the range to analyse (35-450 m/z in our 
case) 
49,50
.  
In order to develop the targeted analysis of FFAs in serum, derivatization is needed. 
However, the use of GC-MS is still vulnerable to surface contamination, mass 
calibration, and other effects that influence mass resolution and accuracy. In order to 
avoid this, repeatability conditions should be assured by the use of quality control (QC) 
samples. According to ISO 15189 “The laboratory shall use quality control materials 
that react to the examining system in a manner as close as possible to patient samples” 
and “Quality control data shall be reviewed at regular intervals to detect trends in 
examination performance that may indicate problems in the examination system.”26. 
These guidelines provide the basis for QC of our method, allowing repeatability 
conditions for each obtained metabolic feature (chromatographic peak that results from 
retention index and mass spectrum), and consequently for each detected metabolite 
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(identified with one or more metabolic features). To reduce the bias in the data analysis, 
a randomization of the samples in each run and in between runs is necessary. In this 
way, systematic errors can be avoided and the proper performance of the analytical 
system can be evaluated by the continuous monitoring of the QC samples. In our work, 
these QC samples are made of a pooled mix of all the samples to be analysed in the 
study and undergo the same derivatization process as the study samples, being also 
spiked with internal standard (allowing to account for variability in sample processing 
and in the analytical system). In this way, it is ensured that the QC samples will behave 
in a similar way as the study samples. 
In the quality assurance (QA) process, a continuous monitoring of QC samples will 
allow for outlier removal when significant drift in signal, mass or retention time is 
observed. Quality assurance is evaluated by establishing several parameters. If the 
process complies with these parameters, it can be considered under control; otherwise 
we face an out-of-control situation. The first parameter is to identify if the analytical 
platform is “balanced” (producing a reproducible signal) before the real samples are 
analysed, confirming that the system has all active sites saturated with the sample 
matrix. This is obtained by injecting a number of QC samples (approximately 5) in the 
beginning of each batch
51
. Secondly, there is the estimation of technical precision. 
International guidelines for bioanalytical method validation such as the ones from USA 
Food and Drug Administration (FDA) recommends a general value of 15% for the 
coefficient of variation (CV) and a CV of 20% near the lower limit of quantification 
(LLOQ) 
52
, but other studies mention that due to the derivatization process needed and 
losses in injection in GC-MS, 30% is an acceptable limit for technical precision
49
. In 
practical terms, CV and RSD are the same as long as RSD is represented as a 
percentage, and can be calculated through the ratio between the standard deviation (σ) 
and the mean (µ), as shown in equation 3: 
(3) 𝐶𝑉 = 𝑅𝑆𝐷 × 100% = 𝜎 𝜇⁄ × 100% 
 Nevertheless, a qualitative step was introduced by analysing QC samples in full scan 
mode (QC-scan) in each run, ensuring that metabolic features would be stable. In this 
work, technical precision was set to be lower than 20% RSD, and the QC-scan was 
compared with a standard FAMEs mixture. For the EFA from the serum samples that 
were not in the standard mixture, equivalent chain length (ECL) values were estimated 
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by calculation, and posterior identification was carried on by library comparison
53
. In 
this way is it possible to design the experimental QA process for the analytical method 
used. 
1.2.5 Chemometrics: PCA, CCA and RF 
Chemometrics is defined by Svante Wold as “how to get chemical relevant 
information out of measured chemical data, how to represent and display this 
information, and how to get such information into data”. Massart adds that 
chemometrics aims at designing or selecting optimal measurement procedures and 
experiments and at extracting maximum information from chemical data
54,55
. These 
tools are fundamental for enhancing the achievements of metabolomics studies, 
however they should be applied to pre-processed data rather than to raw data formats. 
After running a GC-MS analysis, data is obtained as a 3D matrix of m/z versus retention 
time versus intensity, as shown in figure 11, in a format supplied by the manufacturer. 
Due to the lack of a universal standardized format for GC-MS data, the original format 
is usually converted into a format that is compatible with pre-processing software. Pre-
processing is needed in order to remove irrelevant information/variables caused by 
several factors such as column aging, experimental variations or sample stability, and 
the most common procedures are baseline correction, chromatogram alignment, 
normalisation, smoothing and peak area integration
49,56–58
.  
Several types of normalisation procedures have been described in literature
59
, but in 
biomarker research it is usually done by setting a default value to the value of internal 
standard (e.g. setting it to 1) and consequently establishing relative values to other 
metabolic features by dividing their original values by the value of the internal standard. 
In this way the relative magnitude of the signal will be revealed and if needed, 
concentrations can be calculated. Smoothing procedures are applied to increase the 
signal-to-noise ratio, promoting the detection of small signals that can be easily 
overlapped by noise. There are several methods used for smoothing, such as moving-
window average smoothing or Savitsky-Golay filter (based on polynomial regression) 
55
. Baseline correction/background correction is often needed due to swamping of the 
signals by the baseline drift, and this is done using algorithms like penalized least 
squares or adaptive iteratively reweighted procedure
55
. Nevertheless, chromatogram 
alignment is essential since it will correct for systematic errors that may occur during 
the analytical run and eventual peak shifts on the chromatogram. One of the most 
  INTRODUCTION 
Page | 21  
 
accurate alignment methods is the recursive alignment by fast Fourier transform 
(RAFFT), where a global scale alignment is performed prior to a local scale alignment, 
having as reference the correlation values between test chromatograms and reference 
chromatograms. As a final alignment step, the optimal warping path is achieved by 
shifting the points of test chromatogram
60
.  Peak integration can often be done on the 
analytical platform software but several alternatives can be found. This should be the 
last pre-processing procedure, after normalising, smoothing, correcting baseline and 
aligning chromatograms. 
After pre-processing and prior to data analysis, it is always necessary to proceed to 
an identification of the metabolic features for FA, a frequently challenging step in 
metabolomics. Most of the identification methods are based on the comparison of mass 
spectra and retention indices with established libraries (e.g. National Institute of 
Standards and Technology (NIST)) or with authentic standards. However, libraries 
often differ between research groups, and results are not so accurate. On the other hand, 
the use of a large amount of standard compounds increases the costs of analysis. One 
alternative strategy is the equivalent chain length (ECL) values determination
53
. In this 
method, a special database is developed using the ECL values and mass spectra 
characteristics. The latter were used to recognize saturated FAMEs and consequently 
calculate the ECL values for unsaturated FAMEs in samples. This strategy overcomes 
the proximity (or overlapping) between retention indices and mass spectra of the 
isomers
55,61–63
. First, after doing the data pre-processing, SIM mode chromatograms are 
extracted in order to identify the expected saturated FAMEs. The retention times of 
these compounds are converted into ECL (the ECL value is defined as the number of 
carbon atoms in the FA carbon chain). Finally, a calibration is done using the retention 
times of the saturated FAMEs, and ECL values for each FA are calculated using the 
saturated FAMEs eluting before and after the compound of interest, as following: 
𝐸𝐶𝐿(𝑥) = 𝑛 +
𝑅𝑇(𝑥) − 𝑅𝑇(𝑛)
𝑅𝑇(𝑛 + 1) − 𝑅𝑇(𝑛)
 
where n and n+1 are the number of carbons of the saturated FAME eluting before and 
after the target compound, respectively. Finally, the ECL value is then compared with 
the ones in the custom database for identification
53
.  
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In general, metabolomics studies provide large datasets with several variables being 
measured for each sample, where the complexity demands more advanced statistical 
tools. Classic statistics may in some cases be insufficient to provide information about if 
a certain metabolite is discriminant or it is simply a statistical artefact
64
. When 
evaluating if FFAs or even if the clinical parameters are statistically different in healthy 
control samples when compared with MetS patients, we face a multiple comparison 
problem due to the simultaneous comparison of several variables. To find statistical 
differences is particularly useful in the way that allows the researcher to understand if, 
in the case of clinical parameters, the diagnosis of a disease makes sense and there are 
mathematical differences between the healthy people and the patients. It is also useful 
for the identification of potential biomarkers, as in the case of finding that a particular 
FFA as significantly different value in between MetS patients and healthy controls. 
These statistical differences are analysed by testing the so called null hypothesis, 
indicated as H0, which refers to the case in which the values of each group are not 
different. A statistical test is then applied in order to decide to accept or reject H0, 
resulting in a p-value. A typically used statistical test is the t-test which compares the 
mean values of each group, and sets a α threshold for the confidence level. Typically α 
is set to 0.05, and the respective confidence level is 1- α which in this case is 0.95, also 
represented as a percentage as 95%. This means that H0 can be rejected with a 
confidence level of 95%. However, there is still the 5% probability of wrongly rejecting 
H0, and this is called a type I error (false positive). On the other hand, a type II error 
may happen when H0 is accepted and in fact it should be rejected (false negative). As 
mentioned before, in multiple comparisons these classical approaches are not 
applicable. The probability of finding significant differences, by chance, increases. One 
of the solutions for this problem is based on the principle of family-wise error rate 
(FWER), which refers that if two classes are not different, their variables should not 
show statistical significant difference. In order to control FWER, Holm proposed an 
improved method to Bonferroni approach known as Bonferroni-Holm correction
65
, in 
which a step-wise approach based on the p values is used, as shown in figure 12. This 
method uses a different α for each variable, being more restrictive with variables that 
show a smaller p value. The smallest p is compared with 
𝛼𝑈𝑉
𝑚⁄  (Bonferroni limit) in 
which 𝛼𝑈𝑉 is the probability of error for each individual test and m is the number of 
individual tests. In each step, this limit is made less conservative
66
. 
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Figure 12: Holm-Bonferroni step-wise approach to control FWER 
66
 
When testing the correlation of two sets of variables (like FFAs and clinical 
parameters), one must variance is equal in both variable sets. One way of doing this is 
by applying Bartlett’s test, making an approximation to the chi-squared distribution67. 
This is where chemometrics, including multivariate data analysis come into play. In a 
traditional case, each object (sample) can be represented graphically with its variables 
(measurements), as shown in figure 13. By representing the values the two variables x 
and y in space, it is possible to obtain a vector r from the origin until the point matching 
the variables values. When several objects have similar measurement values, they will 
be located graphically close to each other forming a cluster. Problems with simple 
representations happen with the number of variables increases, necessitating the use of 
computer analysis and three dimensional plots. Nevertheless, a high number of variables 
increase the chance of having unnecessary information. Multivariate data analysis 
provides methods that enable data reduction through the elimination of redundant 
information
68
.  
Principal component analysis (PCA) is one of the most popular techniques used as a 
starting point in metabolomics exploratory data analysis, and generates principal 
components (PCs) as linear combinations of the initial variables
50,68
.  
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Figure 13: representation of variables xi and yi projecting the vector ri
68
 
As shown in figure 13, the vector r can be projected taking coordinates from the original 
variables x and y. Each specimen X is derived from these original variables and can 
generate the following PCs by linear combination: 
PC1 = a11X1+a12X2+…a1nXn 
PC2 = a21X1+a22X2+…a2nXn 
etc. 
where a11, a12, a21, a22... are the coefficients of the independent new variables X1, X2 and 
Xn. Each PC will contain the variance on the initial dataset, being the first PC the one 
that contains most of the variance, and the last PC with the least variance. By definition, 
each PC is orthogonal to each other (PCA is an orthogonal transformation), as shown in 
figure 14(a), and accordingly they can also be displayed as axes as in figure 14(b). A 
representation of data points onto these axes will show clearly where most of the 
variance resides. From the simultaneous variance of two variables it is possible to 
calculate the coefficient of variation (CV), and a CV matrix will then allow obtaining 
the eigenvectors (each eigenvector is a PC) and their respective eigenvalues (dataset 
variance explained by each PC). On the other hand, the eigenvectors are described by a 
set of coefficients that when multiplied by the variable values of a sample will result in 
scores. When a good PCA is possible, the scores plot often helps to reach conclusions 
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about classification of the variables and their interaction, as shown in figure 15, due to 
their relative location in the plot, making this a good method for visualization of 
trends
58,68
.  
 
Figure 14: representation of Principal Component 1 and Principal Component 2 (a) 
relatively to x1 and x2, (b) with points projected on Principal Component axis, where 
balls are data points and circles are their projection in each axis
68
 
 
Figure 15: scores plot of Principal Component 1 and Principal Component 2
68
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In recent studies it is possible to find novel classification methods based on machine 
learning such as random forests (RF)
69
. Introduced firstly by Breiman in 2001, this 
method is able to classify a dataset by generating random vectors by independent 
sampling. Each vector defines a tree selected from a forest (origin of the method’s 
name), having the same distribution as all the other vectors existing in the forest. This 
tree is then called a predictor. The RF method is based on two distinct techniques: 
decision tree learning and tree bagging. Decision tree learning is the process of 
generating a model that predicts the value of a target variable based on the input, and 
afterwards splitting this input in smaller groups based on the value of the test. This 
splitting is repeated iteratively until the value of the smaller group equals to the value of 
the target variable or when the split shows no change in the value of the predictors. It is 
independent of scaling and some other transformations, which makes it a robust 
method, but the main drawback of this procedure is the low accuracy and the possibility 
of over-fitting the training set (low bias). In other hand, tree bagging was developed to 
add accuracy to the previous method and avoid over-fitting. This last process consists of 
the generation of new training sets from the original data set, and consequent uniform 
sampling with replacement. By definition, this type of sampling will generate a 
bootstrap sample, and each one of them will then lead to a model, which will ultimately 
be voted to provide classification. In short, the more classification trees are built, the 
more accurate becomes the classification process. The estimation of this accuracy is 
done internally by using out-of-bag (OOB) estimation, avoiding the need for cross-
validation. Cross validation in many cases requires the removal of at least one sample 
from the dataset prior to the model construction (PC calculation) and then verify how 
well the removed sample can be predicted by the model
70
.  
Proximities among samples are also possible to be calculated. The number of times 
two samples are classified in the same terminal node of a tree, divided by the total 
number of trees is the value of proximity among these samples. The graphical 
representation of these proximities (similarities and dissimilarities) is done by MDS 
(multidimensional scaling) plots, which represent the proximity set of points in 
Euclidean space based in nonmetric information
71,72
. The RF algorithm for classification 
is introduced as
57,73,74
:  
a. Draw ntree bootstrap samples from the original dataset. (ntree is the number of 
trees in the forest. In our study it was set ntree=600) 
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b. For each of the bootstrap samples, grow an un-pruned classification tree, and 
modify with the following procedure: at each node, randomly select mtry 
variables and choose the best split from among those variables. (For 
classification, the default value of mtry is equal to sqrt(mall) where mall is the total 
number of the variables in the original dataset. In this study, mall=28, thus, 
mtry=5). 
c. Predict new data by aggregating the predictions of the ntree trees. 
An example of the process in decision trees is shown on figure 16, from the study of 
Worachartcheewan et al
75
. In this case the tree is designed for classification of MetS 
status, and the root node is the TG diagnosis factor. Depending if the sample has a value 
higher than 149 mg/dLor not, it will lead to a different internal node. Each decision may 
lead to another question or to a terminal leaf node for decision. 
 
Figure 16: Metabolic syndrome status decision tree classification, in which Yes 
means MetS presence, No means non-MetS. The final output of Yes or No is 
called terminal leaf node and contains one or two numbers in parentheses, which 
represent the number of correctly and incorrectly classified samples, 
respectively
75
. 
As mentioned before, RF algorithm draws a number of tree bootstrap samples for 
classification, but at each node it randomly selects variables and chooses the best split, 
and afterwards aggregates the predictions of all the trees for predicting new data. From 
the final results for the RF model, it is possible to calculate its sensitivity, specificity 
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and accuracy. Classification accuracy is related with the overall percentage of correct 
classification, while sensitivity describes the percentage of correctly classified variable 
in a certain group, and specificity represents the correct classification of a variable out 
of a certain group.
76
 
After obtaining the analyte profiles in the samples, a correlation between these 
profiles and diagnosis is necessary for producing significant results and knowledge 
about the disease mechanisms. A classical method of performing this kind of data 
analysis is canonical correlation analysis (CCA)
73,77,78
. This method works through 
cross-covariance matrices, finding the maximum correlation by generating linear 
combinations of the studied variables (in our case x and y would be the studied 
variables matching FFA and clinical parameters, respectively). After mean centring the 
data, the calculated covariance matrix can be represented as: 
𝐶 =  [
𝐶𝑥𝑥 𝐶𝑥𝑦
𝐶𝑦𝑥 𝐶𝑦𝑦
] = 𝐸 [(
𝑥
𝑦) (
𝑥
𝑦)
𝑇
] 
where 𝐶𝑥𝑥 and 𝐶𝑦𝑦 are the within-sets covariance matrixes of x and y, and 𝐶𝑥𝑦 = 𝐶𝑦𝑥
𝑇
 
which represent the between-sets covariance matrix. The CCA will provide then the 
eigenvalue equations that will result in the correlation values: 
{
𝐶𝑥𝑥
−1𝐶𝑥𝑦𝐶𝑦𝑦
−1𝐶𝑦𝑥?̂?𝑥 = 𝜌
2?̂?𝑥
𝐶𝑦𝑦
−1𝐶𝑦𝑥𝐶𝑥𝑥
−1𝐶𝑥𝑦?̂?𝑦 = 𝜌
2?̂?𝑦
 
Where 𝜌2 is the square of canonical correlations (eigenvalues), and the eigenvectors ?̂?𝑥 
and ?̂?𝑦 are the normalized canonical correlation basis vectors. The smallest 
dimensionalities of x and y will ultimately define the number of possible solutions to 
these equations. Finally, the result is given as the canonical variables U and V, with 
U=Xa and V=Yb. 
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2. Experimental 
2.1 Materials and Reagents 
In the determination of the FAs, a Supelco FAME mix (No. 47885-U) of 37 
component, methyl 10-nonadecenoate and a cis-10-nonadecenoic acid (C19:1n-9c, 
≥99% purity) internal standards (IS), methyl heptadecanoic acid and heptadecanoic acid 
(C17:0, ≥99% purity) IS, were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
For the derivatization steps, a 5% H2SO4/CH3OH solution was freshly prepared through 
dilution of H2SO4 (98,0% purity, Zhuzhou Chemical Industry Institute, Zhuzhou, 
China) with chromatographic grade methanol (Tedia Company, Inc, Fairfield, USA), 
and a 0.4 M KOH/CH3OH solution was freshly prepared by dissolving analytical grade 
KOH in chromatographic grade methanol. Analytical grade n-hexane and anhydrous 
sodium sulphate were commercially obtained from Tianjin Yongda Chemical Reagent 
Co, Ltd (China) and Tianjin Kernel Chemical Reagent Co, Ltd (China), respectively. 
All the procedures were performed using appropriate routine laboratory glassware, 
washed accordingly to routine methods established by the laboratory (including rinsing 
with tap water for large particle removal, methanol immersion and incubation for 30 
minutes at 25 ºC in an ultrasound cleaner, washed with de-ionized water and dried 
overnight in an oven incubator). 
2.2 Serum Samples 
2.2.1 Sample collection 
The serum samples were collected under pre-analytical overnight fasting 
requirements for blood collection
79
, and according to the established standard 
protocols
6
, from 100 Chinese subjects, aged between 25 and 70 years, at the Xiangya 
Hospital of Central South University in Hunan province (China), from February 2012 to 
March 2013. A sample of venous blood (2 mL) was collected in a blank tube without 
anticoagulant or preservative, and was allowed to clot at 4 ºC for 1 h in order to obtain 
the serum. The MetS diagnosis was done following the guidelines on prevention and 
treatment of dyslipidaemia in Chinese adults
80
 adapted from the most recent definition 
of MetS given by CDS in 2004
81
 and by IDF in 2005
82
. Accordingly, MetS patients 
were defined whenever three of the following risk factors were fulfilled: central obesity 
(waist circumference > 90 cm in men, > 85 cm in women), increased blood pressure 
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(SBP/DBP ≥ 130/85 mmHg or previously diagnosed hypertension), increased fasting 
blood glucose (FBG ≥ 6.1 mmol/L or previously diagnosed type 2 diabetes), increased 
serum triglycerides (TG ≥ 1.70 mmol/L) and decreased HDL-cholesterol (HDL-C ≤ 
1.04 mmol/L). The subjects were divided into two groups: healthy controls (HC) group 
where the subjects had 0 risk factors and MetS patients group where the subjects had at 
least 3 of the 5 risk factors. All participants have written an informed consent and 
Xiangya Institutional Human Subjects Committee approved all clinical experiments. 
2.2.2 Sample preparation and derivatization 
After collection, the serum samples were stored at -80 ºC, since previous studies in 
the research group shown that higher temperatures do not allow enough FA stability
83
. 
Sample preparation was carried out according to an adaptation of the procedures 
established by the research group in previous works for FA analysis by GC-MS, as 
shown in figure 5
25
. Initially, a pooling QC sample was prepared by addition of 10 µL 
of each of the serum samples in our study, followed by 1 min vortex mixing
49,84
. 
Aliquots (50 µL) of serum were spiked with 10 µL of 0.1 mg/mL C19:1n-9c IS (in n-
hexane), added to 0.5 mL of 0.4 M of KOH/CH3OH, 30 s vortex mixed and incubated 
for 10 min at room temperature. Afterwards, 0.5 mL n-hexane was added to the 
previous mixture and vortex mixed for 30 s, followed by isolation of the serum phase. 
This step was repeated using the remaining n-hexane phase, and both serum phases 
were collected to the same glass tube. Anhydrous sodium sulphate was added to the 
resulting serum phase followed by vortex mixing, addition of 0.5 mL of 5% 
H2SO4/CH3OH and vortex mixed for 30 s. The mixture was kept in a 70 ºC water bath 
for 30 min and then placed at room temperature for temperature stabilization. To the 
room-temperature mixture was added 1 mL of n-hexane twice with 30 s vortex mixing 
after each addition, the n-hexane phase being isolated each time in the same glass tube. 
The resulting solution was evaporated to dryness under N2 flow, and the remaining 
sediments (FAMEs) were reconstituted with 100 µL of n-hexane for GC-MS analysis. 
2.3 GC-MS analysis 
2.3.1 Optimization and Repeatability 
In order to study the repeatability of the method, a first approach included the 
derivatization and analysis at the facilities of the Research Centre of Modernization of 
Chinese Medicines at the College of Chemistry and Chemical Engineering of Central 
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South University, using a Shimadzu GC2010A (Kyoto, Japan) GC instrument coupled 
to a GCMS-QP2010 MS (Compaq-Pro Linear data system, class 5K software). A DB-
23 capillary column (30 m x 0.25 mm id, film thickness 0.25 µm, Agilent Technologies, 
USA) was used for the FA analysis. Test serum samples from previous approved studies 
in the research group were used in this initial phase and derivatization methods were 
developed according to the previous described method. Repeatability was carried on by 
ensuring the execution of each derivatization step following the established procedures 
and checking the RSD of the spectra obtained with this analytical system. In this initial 
approach IS was C17:0 and C17:0 methyl ester. Optimizations in this process included 
changes in reagents and sample quantity without losing significant signal intensity. The 
optimized temperature program in this GC-MS system is described in table 1, achieving 
a final GC run time of 16.5 min. With an inlet temperature of 250 ºC, the injection was 
performed in split mode with a split ratio of 1:10 in the case of methyl ester FA and 1:5 
for non-methylated FA, for 2 µL of injected sample. The Helium (99.999% purity) 
carrier gas was kept at a constant flow rate of 1.0 mL/min, while the MS conditions 
were: ion source, quadrupole and interface temperature of 230 ºC, 150 ºC and 250 ºC, 
respectively, detector voltage of 1 kV, MS program starting at 4 min and finishing at 
16.5 min, a velocity of 0.2 s/scan, and in SIM mode the selected characteristic m/z for 
FA profiling were 55, 67, 74 and 79, while in full-scan mode the range was 35-450 m/z. 
Table 1: GC-MS optimized temperature program on the Shimadzu analytical system 
Start Time 
(min) 
Rate 
(ºC/min) 
End Time 
(min) 
Final Temperature 
(ºC) 
Hold Time 
(Min) 
0 0 0 70 1 
1 20 4 150 0 
4 6 9 180 0 
9 20 11.5 230 5 
 
2.3.2 Internal Quality Control and Quality Assurance 
Some internal quality control procedures were implemented in order to ensure data 
reliability. N-hexane was selected as the reagent blank (B) and QC samples were in 
each analytical run. Every batch consisted of 12 study samples randomly selected, 
preceded by a minimum of 3 QC sample injections and one QC-scan, including a QC 
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sample every fourth study sample injected and ended with two consecutive QC sample 
injections as shown in the experimental design in table 2. Apart from the QC-scan, all 
other injections were acquired in SIM mode. 
Table 2: Experimental design of sample order for each batch 
Injection Nr 1 2 3 4 5 6 7 8 9 10 11 12 13 
Sample Type QC QC QC QC-Scan S1 S2 S3 B QC S4 S5 S6 B 
 
Injection Nr 14 15 16 17 18 19 20 21 22 23 24 25 26 
Sample Type QC S7 S8 S9 B QC S10 S11 S12 QC QC B B 
 
Nevertheless, after data acquisition and pre-processing, only metabolic features that 
fulfil the quality assurance (QA) requirement of peak area RSD < 20% were able to 
proceed for subsequent data analysis. 
2.3.3 Serum FA profiling of study samples 
After doing an initial optimization of the Shimadzu system, studying the method’s 
repeatability and establishing the experimental design, an optimization of all processes 
in the new analytical system at the facilities of the Xiangya Hospital of Central South 
University was carried out. The GC-MS analyses used an Agilent 7890A GC coupled to 
an Agilent 5975C quadrupole mass spectrometer, using the same capillary column as in 
the preliminary testing with the Shimadzu system. The injector temperature was 250 ºC, 
and it was operated in split mode at a ratio of 1:5 for a sample injection volume of 2 µL. 
Helium (99.999% purity) was used as carrier gas at a 1.0 mL/min flow rate. The 
resulting optimized temperature program is shown in table 2, with a total program time 
of 16.83 min. 
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Table 3: GC-MS optimized temperature program on the Agilent analytical system 
Start Time 
(min) 
Rate 
(ºC/min) 
End Time 
(min) 
Final Temperature 
(ºC) 
Hold Time 
(Min) 
0 0 0 100 1 
1 20 3 160 0 
3 6 6.33 180 3 
9.33 20 11.83 230 5 
 
In the MS component, the transfer line, quadrupole and ion source temperatures were 
250 ºC, 150 ºC and 230 ºC, respectively, and the electron impact (EI) energy was of 70 
eV. In SIM mode the selected characteristic m/z for FA profiling were 55, 67, 74 and 
79, and in full-scan mode the range was 35-450 m/z. In this phase the IS was switched 
to C19:1n-9c, and only FFA were considered for analysis and further identification. 
2.4 FFA identification 
The serum FFA identification was achieved using a combination of a 37 component 
FAME standard mixture with a previous developed method in our research group
53
. The 
method included the automatic recognition of the expected saturated FAMEs through 
their mass spectra, followed by the use of the respective retention times to calculate 
their ECL values and consequently being able to interpolate the ECL for the unsaturated 
FAMEs in the samples. The resulting ECL values and characteristic ions were then used 
for library identification. 
2.5 Data Analysis 
After GC-MS analysis, it was necessary to convert the raw .D format data files into 
NetCDF format, allowing to do the pre-processing using the Traditional Chinese 
Medicine Fingerprint Database System (TCMSys v1.0.2) developed by the research 
group. Using this software, smoothing, baseline correction, peak shift alignment, 
normalization and peak area integration was carried out. The normalization step was 
done using the IS, so the metabolite peak areas were always represented as relative 
intensities to the IS peak area. After QA, the resulting data matrix contained 42 HC, 58 
MetS patients and 49 QC samples, which were afterwards imported into MATLAB 7.10 
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(The MathWorks, Inc., Natick, MA) for multivariate statistical analysis using custom 
scripts. 
With the pre-processed autoscaled data, it was possible to proceed to the PCA where 
the general data trends were observed by the generation of a score plot of PC1, PC2 and 
PC3. Then, RF was applied for classification and obtaining a prediction model for 
MetS, setting the parameters of ntree=600 and mtry=5, and building an MDS plot of the 
results. Finally, CCA was carried on for unveiling the relationship between FFA and the 
clinical parameters. A scatter plot was obtained for all dataset, and absolute value of 
coefficients for both FFA and clinical parameters were represented in a bar plot for 
identifying potential biomarkers and important clinical parameters in disease diagnosis. 
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3. Results and Discussion 
3.1 MetS clinical parameters 
Metabolic syndrome has been reported as cluster of risk factors that lead to 
cardiovascular diseases and type 2 Diabetes Mellitus. These risk factors are currently 
used for the diagnosis of this syndrome and their critical limits are established 
differently around the globe, being most definitions published by IDF, WHO, 
NCEP:ATPIII and CDS. Previous works on the general Chinese population have 
reported the prevalence of MetS using as reference ten city regions and ten rural 
counties, and a four-stage stratified sampling method. This survey accounted with a 
representative sample of 15540 people examined under NCEP:ATPIII MetS definition 
and concluded an incidence of 9.8% in men and 17.8% in women, being the higher 
incidence in northern China and in urban areas
6
. In our study
73
, the population 
undergoing analysis was original from Hunan province in China, and used the CDS 
definition with some adjustments. In comparison with Gu et al (2005), the clinical 
parameters for MetS diagnosis were the same with the exception for the limits of HDL-
C, which were not so strict in our study keeping a value of 1.04 mmol/L for both 
genders while in the former study these values can go up to 1.3 mmol/L in women, 
being the latter more restrictive. For the limits of waist circumference were more 
restrictive with values of 90 cm for men and 85 cm for woman in our study, and being 
allowed to reach 102 cm in men and 88 cm for women in Gu et al (2005). The use of 
these waist circumference limits in the present study is seen here as more suitable for 
the study population, and this becomes evident when taking into account that different 
populations have characteristic genetics and different diets that lead to a change in the 
anthropometric values that are considered as normal. At the Xiangya Hospital of Central 
South University, the sample collection was preformed and MetS was diagnosed 
whenever patients had three of the following five risk factors: waist circumference 
(WC) > 90 cm in men or > 85 cm in women, SBP/DBP ≥ 130/85 mmHg or previously 
diagnosed hypertension, FBG ≥ 6.1 mmol/L or previously diagnosed type 2 diabetes, 
TG ≥ 1.70 mmol/L, and HDL-C 1.04 mmol/L. As a result, it was possible to calculate 
the average values for these risk factors for the MetS and HC individuals, as shown in 
table 4. 
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Table 4: Average values for clinical parameters of the study individuals 
Clinical parameters HC (n = 42) MetS (n = 58) P values 
WC (cm) 76.76 ± 6.87 91.19 ± 4.93 1.1315e-20 
SBP (mmHg) 111.33 ± 9.90 133.00 ± 14.25 9.9910e-13 
DBP (mmHg) 70.95 ± 6.89 85.03 ± 11.00 2.1114e-10 
TG (mmol/L) 0.89 ± 0.41 3.60 ± 2.03 9.9910e-13 
HDL-C (mmol/L) 1.39 ± 0.28 1.06 ± 0.23 4.1058e-09 
FBG (mmol/L) 4.89 ± 0.42 6.91 ± 2.57 2.1097e-06 
values given  as mean ± SD for a confidence level of 95% (P values < 0.05) from T-test 
and adjusted by Bonferroni-Holm correction for multiple comparisons. 
These values suggest that there was a significant difference between average values for 
healthy controls and metabolic syndrome patients. In the case of WC, the values seem 
to present the most significant difference in this table, but may not be suitable for 
comparison with the limits established by the risk factors, since these are different 
between genders. It can clearly be observed here that TG have the values that most 
exceed the critical risk factor limits, with a value of 3.60±2.03 mmol/L exceeding the 
limit of 1.7 mmol/L, and concomitantly presenting a high significance level. 
Triglycerides play an important role in dyslipidaemia processes, being storage 
molecules for FFA. A large quantity of TG may indicate also a large amount of 
circulating FFAs involved in the metabolic disturbance caused by MetS. 
3.2 GC-MS profiling 
After diagnosis, sample collection and storage at -70ºC, sample derivatization took 
place. In a first approach to achieve repeatability and optimized conditions, sample 
derivatization was performed at the Research Centre of Modernization of Chinese 
Medicines. This derivatization was based in previous studies developed in the research 
group
25
, using a Shimadzu GC-MS system. After the first round of tests it was possible 
to confirm that C17:0 methyl ester and C17:0 were not present in the sample and were 
available in the laboratory stock, thus it was decided to use these FA as IS. On the other 
hand, the initial approach in this study aimed at analysing both NEFA and EFA from 
the serum samples in order to confirm previous findings that state the inability of EFA 
to discriminate between disease and control groups in dyslipidaemia processes
25
. 
Accordingly, the initial procedure included also the analysis of the first extract obtained 
  RESULTS AND DISCUSSION 
Page | 34  
 
in the derivatization step instead of discarding it. In the end of this first period, 
experimental conditions allowed to achieve repeatability of the method and optimization 
of the temperature program for FA analysis. 
When moving to the Xiangya Hospital laboratories, a new Agilent GC-MS system 
was employed in the analysis. Thus it was necessary to also test the method’s 
repeatability and optimization of temperature program. In this period it was necessary to 
clean the MS detector according to the manufacturer instructions, replace and clean the 
liner as a routine procedure, replace injector septum regularly, replace the gold seal at 
the beginning of the experiment, install the column that was used in also in the 
Shimadzu system and preform the tuning of the MS detector. After these procedures, 
the analytical system showed good behaviour during the experiment; however two main 
problems were identified. The first one was identified from the tuning report, which has 
shown high levels of air and water. After checking all the possible leaks, it was 
observed that the graphite ferrule, responsible for the isolation of the connection 
between the column and the transfer line that leads to the detector, was broken, having 
half of it around the column and half of it inside the transfer line. This problem 
happened due to an incorrect adjustment of this connection, most probably due to over 
tightening the nut. The high temperatures in these parts of the system lead to the 
blockage of the transfer line by the melt ferrule, problem that was solved by inserting a 
small tool to push this part out. The tuning preformed after the correction of this 
situation confirmed the inexistence of any leakages. The second problem was a large 
overlapping band on the right side of the spectra that was identified as Cholesterol. 
After the study of this problem, it was concluded that the liner cleaning should be done 
in a more frequent manner, and in order to correct this problem it was necessary to run 
several blank samples (n-hexane) for column “washing”. After fixing these problems, 
and confirming the appropriate performance of the equipment, the experiment was 
started. 
During the optimization period with the Agilent system there was the analysis of 
some real samples without IS. These samples revealed an interesting result, which was 
not shown with the Shimadzu system, probably due to the higher resolution capacity of 
the Agilent system. The real samples without IS contained C17:0 in their profile. This 
fact required the change of the selected IS to C19:1n-9c, not present in the real samples. 
An example of the FFA profile is shown in figure 17. 
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Figure 17: Free fatty acid methyl ester profiles by GC-MS from MetS patients (plotted 
upwards) and healthy controls (plotted downwards) 
As can be seen from the previous figure, it is included C19:1n-9c, spiked as an IS. MetS 
patients possess a wide variety of FFA in comparison with HC, an expected result since 
this disease has a characteristic lipid dysregulation. This spectrum also supports the 
results from the clinical parameters in table 4, in which the most relevant risk factor for 
MetS was the high TG values. 
At this point, profiling was only done with NEFA due to time restrictions and 
consequently, EFA were discarded and not used for analysis. This decision was also 
taken considering that EFA analysis was not part of the main objectives of this study 
and taking into account the fact that previous works have proven their inefficiency in 
discrimination of metabolic dyslipidaemia-related diseases
25
. The profiling resulted in 
the identification and quantification of 28 FFAs, as shown in table 5, 22 of them being 
validated with reference standards. 
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Table 5: Free fatty acids profile of MetS patients and healthy control individuals.  
RT (min) FFA HC (n=42) (µg/mL) MetS (n=58) (µg/mL) QC RSD (%) P value 
3.971 C12:0 0.40±0.23 1.02±0.57        9.51 8.9558e-07 
5.217 C14:0 2.59±0.94 5.94±4.13 8.52 2.7682e-05 
5.966 C15:0 0.67±0.14 0.96±0.52 8.91 0.0040 
6.832 C16:0 89.14±18.86 142.96±57.47 5.45 1.7110e-06 
7.023 C16:1n-9c 1.35±0.40 2.31±0.73 9.44 3.6508e-10 
7.103 C16:1n-7c 2.88±1.33 5.49±3.03 6.36 2.2527e-05 
7.862 C17:0 1.46±0.30 1.89±0.58 6.20 3.8969e-04 
8.184 C17:1n-7c 0.20±0.07 0.40±0.30 11.49 8.6202e-04 
9.242 C18:0 37.39±6.78 49.78±16.99 5.09 3.1527e-04 
9.601 C18:1n-9c 56.12±17.59 95.00±39.14 5.14 8.9558e-07 
9.682 C18:1n-7c 4.30±1.31 7.73±3.56 5.33 1.0329e-06 
10.186 C18:2n-6c 72.34±14.68 102.76±45.08 5.54 7.3969e-04 
10.452 C18:3n-6c 0.45±0.23 0.81±0.46 7.29 1.3319e-04 
10.571 C18:3n-3 0.40±0.19 0.69±0.45 6.24 0.0020 
10.764 C18:3n-3c 4.12±1.87 7.39±4.97 6.63 0.0011 
11.315 C20:0 0.47±0.15 0.71±0.51 9.18 0.0322 
11.487 C20:1n-9c 0.74±0.35 1.24±0.61 5.78 1.3243e-04 
11.822 C20:2n-6c 1.33±0.31 1.88±0.63 4.37 2.4112e-05 
12.003 C20:3n-6c 2.83±1.00 4.27±1.77 6.79 1.3905e-04 
12.117 C20:4n-6c 15.08±2.89 17.55±5.43 6.40 0.0462 
12.533 C20:5n-3c 1.07±0.72 1.49±1.14 5.93 0.0948 
12.622 C22:0 0.54±0.15 0.67±0.37 7.76 0.0948 
12.801 C22:1n-9c 0.66±0.20 0.85±0.42 7.35 0.0462 
13.588 C22:4n-6c 0.49±0.11 0.74±0.32 5.79 1.3905e-04 
13.702 C22:5n-6c 0.67±0.23 0.96±0.45 5.94 0.0027 
14.119 C22:5n-3c 1.80±0.41 2.38±0.73 4.45 1.5782e-04 
14.257 C22:6n-3c 6.23±2.19 7.26±2.62 7.83 0.0740 
14.345 C24:1n-9c 0.49±0.16 0.56±0.16 7.53 0.0688 
concentrations reported as mean±SD, for a confidence level of 95% (P value < 0.05), 
adjusted by Bonferroni-Holm correction for multiple comparisons. Underlined FFAs 
showen no statistical significance. 
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From the 28 identified peaks it is possible to observe that 4 of them did not present 
significantly different values (underlined in table 5) between MetS patients and HC, 
with P values for Bonferroni-Holm correction exceeding 0.05. From the remaining 24 
peaks, 22 were identified using reference standards and 2 were identified using the ECL 
method based in the retention indices/retention times and mass spectra information
53
. 
As mentioned before, MetS patients have displayed a wider diversity of FFAs than HC, 
and when present in both groups of samples, FFAs often presented higher values for 
MetS patients. 
3.3 Multivariate data analysis: PCA, RF and CCA 
In order to confirm the general trend that shows a higher diversity and quantity of 
FFAs in MetS patients, it was developed a PCA using a MATLAB script. Before PCA, 
the data was autoscaled (a process of standardisation of the variables in order to 
minimize the dominant effect of metabolites with higher intensity, establishing a similar 
significance among metabolite changes)
70
 and a data matrix of 149 samples (42 HC, 58 
MetS and 49 QC) and 28 variables (the detected metabolic features shown in table 5) 
were considered for further analysis. The score plot of the first 3 PCs shown in figure 18 
was obtained. Accordingly, the first 3 PCs were able to explain 78.25% of all variance 
in data (PC1 63.68%, PC2 9.48% and PC3 5.09%). Although PC1 represents most of 
the variance, it is possible to observe that the separation between the clusters of the 3 
groups of samples happens in the PC2 direction, with a distribution of the MetS samples 
in the negative side, the HC samples in the positive side and the QC samples 
concentrated in the origin. This analysis helps to understand some differences between 
groups of samples; however their classification is not clear enough. 
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Figure 18: PCA scores plot of MetS, HC and QC samples from serum FFA profiles. 
After analysing the initial trends in the dataset, it was applied a more efficient 
classification method: random forests. This methods main advantage can be the 
exemption of cross-validation, allowing an accurate classification and to achieve 
prediction models. As described before, RF is based in the iterative process of tree 
building based on bootstrap samples, and afterwards to test the fitness of the data in 
each tree, calculating the proximities between data from each branch of the tree. This 
machine learning technique was applied using also a MATLAB script on the dataset, 
and an MDS plot was built to represent the proximity matrix in a lower-dimensional 
space, as shown in figure 19. 
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Figure 19: MDS plot of HC, MetS and QC samples from serum FFA, presented in 3 
normalized maximum likelihood (NML) axis 
By observing the MSD plot, it is possible to confirm that a better classification was 
achieved in comparison with the previous PCA method. In both methods, QC samples 
are able to cluster tightly together, which means that along the process the repeatability 
conditions were kept under control, with minimum bias. Furthermore, both groups of 
samples HC and MetS were able to cluster together with no major dispersion, obtaining 
a clear classification. The prediction model developed with RF resulted in a sensitivity 
of 0.8611, specificity of 0.8644 and accuracy of 0.8632. 
In a third data analysis step, it was explored the importance of each of the clinical 
parameters and each of the FFA in MetS by CCA. This method allows to access the 
correlation between the two sets of variables (clinical parameters and FFA), by 
generating linear combinations of these. As shown in table 4, five risk factors take part 
in the diagnosis of MetS (SBP and DBP are considered as the same clinical factor, 
although they have their own limit values) and, as discussed previously, these are often 
related with general dyslipidaemia processes which involve also FFA. In this work, 
CCA is applied in the attempt of unveiling which degree of correlation may exist 
between these, and to identify potential biomarkers in this interaction. CCA general 
workflow passes through the analysis of correlation between covariance matrices of two 
datasets (in this case FFA and clinical parameters), resulting in the generation of two 
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canonical variables which in our case the first two were U1 (as the FFA) and V1 (as the 
clinical parameters). By plotting our data as function of these two variables, as shown in 
figure 20, it can be seen a demonstration of a high correlation with a canonical 
correlation coefficient of 0.9015. 
 
Figure 20: Scores plot of HC and MetS samples as function of canonical variables U1 
and V1. P value of right-tail is calculated from Bartlett’s approximate chi-square for H0 
These results confirm the initial expectations that FFAs are in fact highly correlated 
with the clinical parameters. As it can be observed in the plot the P value is very low, 
which demonstrates the high level of significance of these results when tested by 
Bartlett’s approximate chi-squared statistics for null hypothesis. Nevertheless, CCA can 
also be used to estimate the variables that have most of the covariance responsible for 
the correlation. This is done by taking the coefficients of the canonical variables and 
plotting the absolute values of each study variable. In the case of clinical parameters, it 
is possible to observe in figure 21 that HDL-C, TG and FBG assume most of the 
correlation with the FFAs, showing high absolute values for their coefficients. When 
coupling these results with the ones on table 4, it is possible to observe that FBG and 
TG not only are the parameters that are more intensively expressed in the overall 
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observations for the MetS patients group, but are also the ones that are mostly correlated 
with FFAs. On the other hand, HDL-C shows a much higher correlation with FFAs 
although it initially does not seem to have such a strong effect in the disease diagnosis. 
 
Figure 21: Absolute values of canonical coefficients for each clinical parameter 
When plotting the FFAs absolute canonical coefficient values, it can be observed from 
figure 22 that C16:1n-9c (palmitoleic acid), C20:1n-9c (11-eicosenoic acid), C22:0 
(docosanoic acid) and C22:4n-6c (adrenic acid), are the main responsible for the 
correlation between FFAs and clinical parameters. Recalling the results from table 5 it 
can be noted that C22:0 has no significant difference between MetS and HC samples, 
and consequently should be disregarded as potential biomarker. This effect seems to be 
due to the high canonical correlation of this FFA with the clinical parameters, which is 
possible, although it is not determinant to be a biomarker, since its value is not 
statistical significant in between the HC and the MetS group, being this FFA equal 
important in the absence of clinical risk factors. 
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Figure 22: Absolute values of canonical coefficients for FFAs 
As potential biomarkers, palmitoleic acid, 11-eicosenoic acid and adrenic acid (AdA) 
should be considered not only by their presence in the MetS patients serum and their 
high correlation with the clinical parameters that allow MetS diagnosis, but also by their 
possible role within the biological pathways that can influence direct or indirectly the 
disease mechanisms of MetS. Metabolomics studies often face challenging result 
interpretations due to the complex web of metabolic pathways that allow biological 
systems to work. Particularly FFAs are involved in lipid metabolism, and the 
interactions which involve this process. Palmitoleic acid has its origin in the β-oxidation 
of oleic acid, and it has been reported as being associated with obese prepubertal 
children incidence of MetS
85
. Its importance has also been recognized due to its 
significant higher concentration in an a priori analysis of individuals that have 
developed MetS. This retrospective study compared MetS patients with control 
individuals, considering palmitoleic acid as the most discriminant FFA in the RF 
classification
86
. On the other hand, 11-eicosenoic acid is involved in the conversion of 
oleic acid to nervonic acid, the latter being connected to negative effects on the risk 
factors that lead to obesity-related metabolic disorders
87
. Moreover, previous studies 
also report the higher concentration of 11-eicosenoic acid in diabetic rats
88
, which are in 
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agreement with our findings that this FFA can be involved in the disease mechanism of 
MetS, a metabolic disorder that involves risk factors for T2DM. Finally, AdA has its 
origin in arachidonic acid, which apart from being its precursor can also be its end 
product, in case AdA undergoes a β-oxidation reaction89. This FAA has not been 
reported to be involved particularly in metabolic disorders, however it is strongly 
associated with essential physiological processes
90
, and consequently may play also a 
role in MetS mechanisms. 
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4. Conclusions 
In order to explore the relationship of serum FFA profiles of Chinese individuals 
with MetS, a metabolomics strategy was developed; coupling GC-MS metabolic 
profiling with chemometrics strategies involving PCA, RF and CCA. 
The development of repeatability conditions was essential to achieve reliable results 
and quality data analysis. Such conditions were achieved through the development of 
preliminary training with derivatization methods and study of the test samples, allowing 
optimized temperature programs for GC-MS analysis to be achieved. Moreover, the 
internal QC was possible by establishing an adequate IS, C19:1n-9c, and the use of QC 
samples developed from a pool of the test samples which ensured that QC samples will 
contain the common characteristics of the test samples. A continuous assessment of QC 
samples allowed tracking the stability of the analysis conditions, and the establishment 
of RSD limits for FFA profiling completed the QA before applying chemometrics 
methods. The GC-MS FFA profiling is a fast method, with a total run time of 16.83 
min, and results show that using an experimental design for internal quality control and 
quality assessment of data allow keeping relatively low losses in data (only four out of 
28 metabolic features did not pass the QA requirements). Furthermore, metabolic 
feature identification was possible by using a combination of reference standards and 
ECL method. 
The results of the PCA showed the main trends in the obtained dataset, revealing the 
reliability of the analysis from the close cluster of the QC samples in a scores plot of 
3PCs explaining a total variance of 78.25%. However, the MetS and HC groups did not 
show a clear separation and clustering. From RF was possible to improve the previous 
classification results, being able to describe a better discrimination of the MetS and HC 
group, and also showing a close cluster of the QC samples, achieving a classification 
accuracy of 0.8632. These results suggest that RF can provide good classification 
results for MetS serum FFA profiling samples, and can be a potential tool for disease 
diagnosis. 
Correlation between FFA profiles and clinical parameters for MetS diagnosis was 
estimated by CCA. A high correlation was found, with a canonical correlation 
coefficient of 0.9015. Results from clinical parameter diagnosis of MetS patients 
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showed a preliminary dominance of TG in the overall risk factor analysis, showing a 
high difference between HC and MetS patients. However, CCA demonstrated that not 
only TG, but also HDL-C and FBG had the major influence in the correlation between 
clinical parameters and FFA. In fact, HDL-C was identified as the main responsible by 
this correlation with the highest canonical coefficient. It is clear from the results that 
mechanisms involving lipid metabolism are responsible for the causal effects of MetS. 
In other hand, CCA of FFA shown that C16:1n-9c, C20:1n-9c, and C22:4n-6c were 
the highest correlated FFA with the clinical parameters, having the later the highest 
canonical coefficient value. These FFA have been described in literature as relevant in 
metabolic dyslipidaemia disorders and are in this study identified as potential 
biomarkers for MetS. 
Finally, this approach brings novel information about GC-MS analysis of serum FFA 
profiling of Chinese MetS patients, and results suggest that it can been very effective for 
biomarker identification, metabolic dysregulation analysis and for assisting in disease 
diagnosis and clinical information. 
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5. Future Work 
Further research in metabolic syndrome mechanisms and causal effects is clearly 
needed. From this study it is suggested that lipids and particularly FFAs are the key 
points to unveil the main disease pathways. 
In this study, the general analysis of clinical parameters was made and conclusions 
were taken from the main responsibles for the correlation between clinical parameters 
and FFAs. It would be interesting to confirm if the establishment of a new MetS dataset 
including only patients with HDL-C, TG and FBG risk factors would still be 
significantly different from the HC, and if we would still obtain the same FFA for 
potential biomarkers. 
RF is able to provide feedback about variable importance measures, and 
consequently this can be estimated and compared with the results of CCA analysis, 
allowing to confirm if the FFAs that are highly correlated with the clinical parameters 
are the same as the ones that are the main responsibles for the discrimination between 
the HC and MetS group in RF classification. 
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